Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

[Clinical usefulness of diagnostic methods for human papilloma virus dependent lesions].

Suwalska A, Owczarek W, Fiedor P.

Pol Merkur Lekarski. 2014 Feb;36(212):129-32. Review. Polish.

PMID:
24720112
2.

Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.

Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, Howard M, Chong S, Daya D, Chapman W, Chernesky M.

CMAJ. 2000 Sep 5;163(5):513-8.

3.
4.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
5.

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ.

Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Review.

PMID:
18847555
6.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

7.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

8.

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group.

J Natl Cancer Inst. 2008 Apr 2;100(7):492-501. doi: 10.1093/jnci/djn065. Epub 2008 Mar 25.

9.

Human papillomavirus and genital cancer.

Rapose A.

Indian J Dermatol Venereol Leprol. 2009 May-Jun;75(3):236-43; quiz 243-4. doi: 10.4103/0378-6323.48429. Review.

10.

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group.

J Natl Cancer Inst. 2006 Jun 7;98(11):765-74.

11.

Risk factors for cervical neoplasia in Denmark.

Kjaer SK.

APMIS Suppl. 1998;80:1-41.

PMID:
9693662
12.

[Human papillomavirus typing in routine cervical smears. Results from a series of 3778 patients].

Levert M, Clavel C, Graesslin O, Masure M, Birembaut P, Quereux C, Gabriel R.

Gynecol Obstet Fertil. 2000 Oct;28(10):722-8. French.

PMID:
11244634
13.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
14.

Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.

Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikström I, Wilander E.

Br J Cancer. 2011 Aug 23;105(5):694-7. doi: 10.1038/bjc.2011.277. Epub 2011 Aug 2.

15.

Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force.

Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU.

Ann Intern Med. 2011 Nov 15;155(10):687-97, W214-5. doi: 10.7326/0003-4819-155-10-201111150-00376. Epub 2011 Oct 17. Review. Erratum in: Ann Intern Med. 2012 Jan 3;156(1 Pt 1):71-2.

PMID:
22006930
17.

Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.

Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, Laurila P, Tarkkanen J, Anttila A.

BMJ. 2012 Nov 29;345:e7789. doi: 10.1136/bmj.e7789.

18.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

19.

Human papillomavirus infection and cervical cancer prevention in Japan and Korea.

Konno R, Shin HR, Kim YT, Song YS, Sasagawa T, Inoue M, Park JS.

Vaccine. 2008 Aug 19;26 Suppl 12:M30-42. doi: 10.1016/j.vaccine.2008.05.006.

PMID:
18945412
20.

Cervical cancer: screening and prevention.

Behtash N, Mehrdad N.

Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):683-6. Review.

Items per page

Supplemental Content

Write to the Help Desk